Alberta Investment Management Corp grew its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 84.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 550,000 shares of the medical equipment provider's stock after buying an additional 252,106 shares during the period. Alberta Investment Management Corp owned 0.29% of Zimmer Biomet worth $48,856,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Tacita Capital Inc purchased a new stake in Zimmer Biomet in the 2nd quarter worth about $26,000. Ancora Advisors LLC bought a new stake in Zimmer Biomet in the 2nd quarter valued at about $29,000. Elevation Wealth Partners LLC raised its stake in Zimmer Biomet by 145.9% in the 2nd quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider's stock valued at $33,000 after acquiring an additional 229 shares during the period. Cassaday & Co Wealth Management LLC purchased a new stake in Zimmer Biomet during the first quarter valued at about $44,000. Finally, Parvin Asset Management LLC purchased a new stake in Zimmer Biomet during the second quarter valued at about $47,000. Institutional investors own 88.89% of the company's stock.
Analysts Set New Price Targets
A number of brokerages recently commented on ZBH. Weiss Ratings upgraded shares of Zimmer Biomet from a "hold (c-)" rating to a "hold (c)" rating in a research note on Monday, September 14th. Robert W. Baird set a $104.00 price objective on shares of Zimmer Biomet in a report on Thursday, August 6th. Barclays lifted their price objective on shares of Zimmer Biomet from $100.00 to $115.00 and gave the company an "equal weight" rating in a research note on Monday, November 9th. Zacks Research raised shares of Zimmer Biomet from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 25th. Finally, Wall Street Zen raised shares of Zimmer Biomet from a "hold" rating to a "buy" rating in a report on Saturday. Seven investment analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Zimmer Biomet currently has an average rating of "Hold" and a consensus price target of $112.74.
Get Our Latest Stock Analysis on Zimmer Biomet
Insider Activity at Zimmer Biomet
In related news, insider Kevin R. Thornal sold 5,691 shares of the firm's stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $92.95, for a total value of $528,978.45. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Chad F. Phipps sold 3,000 shares of Zimmer Biomet stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $98.35, for a total transaction of $295,050.00. Following the sale, the insider owned 65,231 shares of the company's stock, valued at approximately $6,415,468.85. The trade was a 4.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 1.28% of the stock is currently owned by corporate insiders.
Zimmer Biomet Stock Down 0.0%
ZBH stock opened at $103.18 on Monday. The stock has a 50-day simple moving average of $95.76 and a two-hundred day simple moving average of $92.57. Zimmer Biomet Holdings, Inc. has a twelve month low of $79.12 and a twelve month high of $112.54. The firm has a market capitalization of $19.53 billion, a PE ratio of 26.12, a PEG ratio of 2.42 and a beta of 0.50. The company has a quick ratio of 0.79, a current ratio of 1.46 and a debt-to-equity ratio of 0.49.
Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.88 by $0.02. Zimmer Biomet had a net margin of 8.95% and a return on equity of 13.02%. The firm had revenue of $2.06 billion for the quarter, compared to the consensus estimate of $2.04 billion. During the same period in the prior year, the firm posted $1.90 earnings per share. The company's revenue for the quarter was up 3.1% on a year-over-year basis. On average, equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.56 EPS for the current fiscal year.
Zimmer Biomet Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th were issued a dividend of $0.24 per share. The ex-dividend date of this dividend was Wednesday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.9%. Zimmer Biomet's payout ratio is presently 24.30%.
About Zimmer Biomet
(
Free Report)
Zimmer Biomet Holdings, Inc. develops and manufactures medical devices and technologies used in musculoskeletal care. Its products support orthopedic procedures involving the hip, knee, shoulder, and extremities, as well as trauma care, sports medicine, and related surgical applications. The company also offers surgical technologies, including robotic and digital solutions designed to assist clinicians with planning and performing procedures. Its products and services are used by hospitals, surgeons, and other healthcare providers.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zimmer Biomet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zimmer Biomet wasn't on the list.
While Zimmer Biomet currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.